Focused On-demand Library for Lysine-specific demethylase 4C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Gene amplified in squamous cell carcinoma 1 protein; JmjC domain-containing histone demethylation protein 3C; Jumonji domain-containing protein 2C; [histone H3]-trimethyl-L-lysine(9) demethylase 4C

Alternative UPACC:

Q9H3R0; B4E1Y4; B7ZL46; F5H347; F5H7P0; O94877; Q2M3M0; Q5JUC9; Q5VYJ2; Q5VYJ3


Lysine-specific demethylase 4C, known by alternative names such as Gene amplified in squamous cell carcinoma 1 protein and Jumonji domain-containing protein 2C, plays a pivotal role in the histone code. It specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, crucial for gene expression regulation, without affecting other lysine residues. This selective activity highlights its unique position in epigenetic mechanisms.

Therapeutic significance:

Understanding the role of Lysine-specific demethylase 4C could open doors to potential therapeutic strategies. Its specific function in demethylating histone H3 positions it as a key player in epigenetic regulation, offering insights into novel approaches for disease intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.